☆ 4.6 Article

A blood biomarker test for brain amyloid impacts the clinical evaluation of cognitive impairment

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Related references

Note: Only part of the references are listed.

Article Medicine, General & Internal

Lecanemab in Early Alzheimer's Disease

Christopher H. van Dyck et al.

Summary: Lecanemab, a humanized monoclonal antibody, reduced amyloid markers and showed improvement in cognition and function in early Alzheimer's disease patients. However, it also resulted in adverse events. Longer trials are needed to determine its efficacy and safety in early Alzheimer's disease.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

Add to Collection

Article Clinical Neurology

Independent study demonstrates amyloid probability score accurately indicates amyloid pathology

Ilana Fogelman et al.

Summary: This study provides additional evidence that the pre-established APS algorithm of the PrecivityAD blood test can distinguish between individuals with amyloid positivity and negativity, and shows good diagnostic performance in both cognitively impaired and healthy individuals. Exploratory data suggests that APS retains its diagnostic performance in healthy individuals, supporting further screening studies in the cognitively unimpaired.

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2023)

Add to Collection

Article Clinical Neurology

Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques

Yan Li et al.

Summary: This study demonstrates that plasma A beta 42/A beta 40 assay is an accurate diagnostic tool for classifying amyloid PET status. The assay performs similarly in both cognitively unimpaired and impaired individuals, and its accuracy improves with APOE epsilon 4 carrier status.

NEUROLOGY (2022)

Add to Collection

Review Radiology, Nuclear Medicine & Medical Imaging

The Role of Amyloid PET in Imaging Neurodegenerative Disorders: A Review

Marianne Chapleau et al.

Summary: This article provides an up-to-date overview of the application of amyloid PET in neurodegenerative diseases, including analysis of clinical, pathological, and imaging data, comparison with other available biomarkers, and review of its use in clinical trials and clinical utility studies.

JOURNAL OF NUCLEAR MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Assessment of a Plasma Amyloid Probability Score to Estimate Amyloid Positron Emission Tomography Findings Among Adults With Cognitive Impairment

Yan Hu et al.

Summary: This study investigates the clinical performance of a diagnostic algorithm incorporating plasma amyloid-beta (A beta) 42:40 ratio, patient age, and apoE proteotype to identify brain amyloid status.

JAMA NETWORK OPEN (2022)

Add to Collection

Review Clinical Neurology

The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease

Oskar Hansson et al.

Summary: Blood-based markers have the potential to revolutionize the diagnosis and prognosis of Alzheimer's disease and improve the design of clinical trials. However, further research is needed before widespread use.

ALZHEIMERS & DEMENTIA (2022)

Add to Collection

Article Clinical Neurology

Blood Biomarkers from Research Use to Clinical Practice: What Must Be Done? A Report from the EU/US CTAD Task Force

D. Angioni et al.

Summary: This article discusses the challenges in diagnosing Alzheimer's disease and the potential use of blood-based markers in clinical practice, as well as the next steps needed for their broader adoption.

JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE (2022)

Add to Collection

Editorial Material Clinical Neurology

Rapid Progress Toward Reliable Blood Tests for Alzheimer Disease

Elisabeth H. Thijssen et al.

JAMA NEUROLOGY (2021)

Add to Collection

Article Medical Laboratory Technology

The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis

Kristopher M. Kirmess et al.

Summary: The PrecivityAD (TM) test developed by C2N quantifies A beta isoforms and APOE isoform-specific proteotyping accurately and with high precision. The results show that the test is sensitive, linear over a wide analytical range, free from significant interferences, and suitable for use in clinical laboratories.

CLINICA CHIMICA ACTA (2021)

Add to Collection

Article Clinical Neurology

Assessment of Racial/Ethnic Disparities in Timeliness and Comprehensiveness of Dementia Diagnosis in California

Elena Tsoy et al.

Summary: The study discovered that in the United States, elderly individuals of Asian, Black, and Hispanic descent were less likely to receive timely diagnoses of dementia compared to White individuals, and they also tended to have less comprehensive diagnostic evaluations.

JAMA NEUROLOGY (2021)

Add to Collection

Review Clinical Neurology

Diagnosis of Early Alzheimer's Disease: Clinical Practice in 2021

A. P. Porsteinsson et al.

Summary: Alzheimer's disease is a progressive and irreversible neurodegenerative disease that affects cognition, function, and behavior. Early and accurate diagnosis is crucial for patients and caregivers to plan for the future and make lifestyle changes. However, detecting early-stage Alzheimer's disease in clinical practice can be challenging and is hindered by various barriers.

JPAD-JOURNAL OF PREVENTION OF ALZHEIMERS DISEASE (2021)

Add to Collection

Article Medicine, General & Internal

Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia

Gil D. Rabinovici et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2019)

Add to Collection

Article Clinical Neurology

High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis

Suzanne E. Schindler et al.

NEUROLOGY (2019)

Add to Collection

Article Clinical Neurology

Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort The ABIDE Project

Arno de Wilde et al.

JAMA NEUROLOGY (2018)

Add to Collection

Article Geriatrics & Gerontology

Effectiveness of Florbetapir PET Imaging in Changing Patient Management

Michael J. Pontecorvo et al.

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2017)

Add to Collection

Article Geriatrics & Gerontology

Effect of Amyloid Imaging on the Diagnosis and Management of Patients with Cognitive Decline: Impact of Appropriate Use Criteria

Michael Grundman et al.

DEMENTIA AND GERIATRIC COGNITIVE DISORDERS (2016)

Add to Collection

Article Clinical Neurology

Assessment of the Incremental Diagnostic Value of Florbetapir F 18 Imaging in Patients With Cognitive Impairment The Incremental Diagnostic Value of Amyloid PET With [18F]-Florbetapir (INDIA-FBP) Study

Marina Boccardi et al.

JAMA NEUROLOGY (2016)

Add to Collection

© Peeref 2019-2024. All rights reserved.